Actively Recruiting
Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis
Led by Hopital Foch · Updated on 2026-01-16
180
Participants Needed
1
Research Sites
274 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Women suffering from endometriosis and/or adenomyosis may also suffer from infertility. GnRH agonist injection could improve implantation and therefore increase the pregnancy rate in these patients. This study was designed to evaluate effects of the additional of GnRH agonist (single or 2 doses) to the routine oestrogens and progestins use as support before Frozen Embryon Transfer as compared to oestrogens and progestins only.
CONDITIONS
Official Title
Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 18 to 36 years with endometriosis and/or adenomyosis
- Planned frozen embryo transfer of a blastocyst after in vitro fertilization or intracytoplasmic micro-injection with freeze all
- Normal uterine cavity
- MRI confirmation of endometriosis and/or adenomyosis at inclusion
- Signed informed consent
- Affiliated to a Health Insurance Plan
You will not qualify if you...
- Age under 18 or 36 years and older
- Body mass index over 35
- History of two or more implantation failures
- Endometrial alterations such as synechiae, polyps, myomas, hyperplasia, or hematometra
- Known unilateral or bilateral hydrosalpinx
- MRI showing no endometriosis or adenomyosis
- Hypersensitivity to GnRH, GnRH analogues, or Decapeptyl 3 mg excipients
- Known hypersensitivity to estradiol, progesterone, acetylsalicylic acid, nonsteroidal anti-inflammatory drugs, folic acid, cefixime, cephalosporin antibiotics, levofloxacin, or quinolones
- History of tendinopathies related to fluoroquinolones
- Epilepsy
- Hypersensitivity to MRI contrast agents
- Known or suspected breast or genital tract cancer
- Known or suspected estrogen-dependent malignant tumors
- Undiagnosed genital bleeding
- Untreated endometrial hyperplasia
- History or current venous thromboembolic events
- Recent or evolving arterial thromboembolic events such as angina or myocardial infarction
- Acute or history of liver disease until liver tests normalize
- Severe kidney failure
- Severe uncontrolled heart failure
- Active gastroduodenal ulcers
- Asthma caused by salicylates or similar drugs
- GnRH agonist Decapeptyl given within 6 months prior to transfer
- Being deprived of liberty or under guardianship
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hopital Foch
Suresnes, France, 92150
Actively Recruiting
Research Team
E
Elisabeth Hulier-Ammar, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here